Outcomes are poor for patients with myelofibrosis who discontinue ruxolitinib due to loss of response or intolerance. In this commentary, I offer my thoughts on the best treatment options for these patients.
In this commentary, Raajit K. Rampal, MD, PhD, highlights key MPN studies that will be presented at the upcoming 2019 ASH annual meeting in Orlando.
Read expert answers to key questions from the audience at a recent symposium on optimal management of patients with myeloproliferative neoplasms.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.